Safety, Tolerability and Pharmacokinetics of Milademetan Alone and With 5-Azacitidine (AZA) in Acute Myelogenous Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Clinical trial NCT02319369 · TERMINATED
Trial details
- NCT number
- NCT02319369
- Sponsor
- Daiichi Sankyo
- Status
- TERMINATED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2014-11-25
- Primary completion
- 2020-08-21
- Enrollment
- 74
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.